ERGによる前立腺がんの発症は細胞環境に依存し,KMT2AとDOT1Lが必要である

Weiran Feng^1,2,3, Erik Ladewig⁴, Matthew Lange⁵

¹Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. weiran.feng@fccc.edu.

Nature genetics

|August 26, 2025

まとめ

ERGは前立腺がんにおける腫瘍を誘発する基礎細胞を活性化し,中間細胞の増殖を促します. これらの細胞は光細胞に変化しその存在は人間の癌の予後が悪いことを示します

科学分野:

前立腺がんの研究
癌細胞生物学
分子腫瘍学

背景:

ERG転写因子の転位は前立腺がんでは一般的であるが,その腫瘍発生機構は不明である.
ERGの役割を理解することは,標的治療の開発に不可欠です.
ERG誘発性前立腺がんに関与する特定の細胞タイプを特定することは不可欠です.

研究の目的:

前立腺がんにおけるERGによる腫瘍発生性のメカニズムを解明する.
ERG陽性前立腺腫瘍の発症の原因となる特定の細胞群を特定する.
ERGによる前立腺がんの進行における中間細胞の役割を調査する.

主な方法:

細胞集団を追跡するために,ネズミのモデルで系統を追跡する.
ERG陽性のヒト前立腺がんのトランスクリプトミア分析
細胞状態と分子特性を特定するための単細胞分析.
生体内腫瘍発生性試験

主要な成果:

腫瘍を誘発するERG活動は,稀な基礎細胞に存在するが,光細胞ではない.
ERGの活性化により,基礎細胞が増殖性中間細胞 (IM) を形成し,その後,光細胞へと移行する.
ヒト前立腺がんのERG⁺細胞は,より悪い予後と相関し,特定のクロマチンの状態と遺伝子発現パターン (STAT3,KMT2A/MLL1,DOT1L) を表している.

結論:

ERGは前立腺の腫瘍形成を特定の基底細胞の系統を通して推進し発光性特性を獲得する.
中間細胞はERGが誘発する前立腺がんの進行において重要な役割を果たし,悪い結果と関連しています.
ERG⁺細胞における特定の分子経路 (STAT3,KMT2A/MLL1,DOT1L) をターゲットにすることが,潜在的な治療戦略を示している.

さらに関連する動画

10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.1K

06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

8.8K

関連する概念動画

03:03

mTOR Signaling and Cancer Progression

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

3.9K

01:24

Small GTPases - Ras and Rho

4.2K

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

4.2K

01:35

Cancer Cell Migration through Invadopodia

2.4K

Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...

2.4K

02:38

Mitogens and the Cell Cycle

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.6K

02:07

Tumor Progression

6.5K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

6.5K

02:30

Metastasis

5.7K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...